Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average recommendation of “Hold” from the ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will ...

Baird downgraded Carisma Therapeutics (CARM) to Neutral from Outperform with a price target of $1, down from $10. Carisma earlier this week announced plans to undergo a strategic restructuring ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024, alongside significant progress in its clinical and preclinical ...

Carisma Therapeutics Inc. has entered into a master services agreement with Danforth Global, Inc. and Danforth Advisors, LLC to receive finance and accounting services from Natalie McAndrew ...

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Monday,Benzinga reports.

In a report released yesterday, Justin Zelin from BTIG maintained a Hold rating on Carisma Therapeutics (CARM – Research Report). The company’s shares closed yesterday at $0.45. Discover ...

Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.

Short interest in CARISMA Therapeutics Inc (NASDAQ:CARM) decreased during the last reporting period, falling from 537.68K to 437.88K. This put 1.31% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Carisma Therapeutics (CARM – Research Report) received a Hold rating and price target from BTIG analyst Justin Zelin today. The company’s shares closed today at $0.78. Pick the best stocks and ...